Private Placement

A DIY system promises water from thin air amid global uncertainty. We investigate if the Joseph's Well program is a real solution or just hot air.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

After a strategic pivot and R&D setbacks, Korro Bio secures an $85M lifeline to advance its novel RNA-editing drug for rare metabolic diseases.

With a new strategic finance leader, MATEREAL signals a shift from R&D to aggressive commercialization of its 'drop-in' AI-enabled bio-polymers.

A European firm is bringing passive brain-computer interface tech to the US, promising safer AI but raising profound questions about mental privacy.

Genspark.ai launches its first 'AI employee,' crossing a $200M run rate and securing a $1.6B valuation in the race to automate knowledge work.

Rivian unveils the R2, a mid-size SUV starting around $45,000. It packs clever features and impressive range, but can the company scale production to meet demand?

Crusoe unveils its 'AI Factory' in a box, deploying high-performance, sovereign AI infrastructure anywhere in months, not years, shaking up the market.

Known for smart vacuums, Dreame is storming the premium phone market with modular cameras, a luxury line, and a bold $1.38 billion R&D gamble.

A live, on-chain invoice payment using Ripple's new stablecoin signals a major shift from slow, traditional finance to instant, auditable B2B transactions.

Origis Energy's rapid expansion to over 2.3 GW reflects surging US demand for clean power, driven by tech giants like Meta and the booming AI industry.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

Harmonic's new media server promises double the channel density at half the cost, targeting IP, cloud, and AI workflows for future-proof broadcasting.

Aclarion brings its AI-powered diagnostic tool, NOCISCAN, to a top investor summit, aiming to revolutionize chronic back pain treatment. Can it succeed?

A new AI-driven platform is tackling AI's energy crisis, promising a massive capacity boost for data centers without costly grid upgrades.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

With its new $165M fifth fund, StageOne Ventures doubles down on Israel's AI and enterprise tech, reinforcing the nation's resilient innovation ecosystem.

A landmark study validated by Optum shows a virtual care model for women saves thousands, shifting benefits from a cost center to a strategic investment.

Bel Group's massive $200M investment in its South Dakota Babybel plant will double production, add 150 jobs, and capitalize on America's new snacking habits.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.